GlassScriptPhysician profile
Kaveh Saremi
NPI 1447437769
$13,742.72
in general payments reported to CMS, 2019-2025
46 companies · $3,840 in 2025
The $3,840 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $678 · 2021: $2,276 · 2022: $1,684 · 2023: $1,671 · 2024: $3,081 · 2025: $3,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,193 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,193.44 |
| Education | $398.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,026.22 | 2020-2025 | |
| Abbvie INC. | $1,702.32 | 2021-2025 | Ubrelvy, Botox |
| Neurocrine Biosciences, INC. | $802.30 | 2019-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $740.49 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $691.38 | 2019-2025 | Ultomiris |
| Eisai INC. | $664.77 | 2019-2025 | |
| Biogen, INC. | $584.66 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Teva Pharmaceuticals USA, INC. | $559.23 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Merz Pharmaceuticals, LLC | $549.52 | 2021-2025 | Xeomin, Inbrija |
| Pfizer INC. | $516.46 | 2023-2025 | |
| Ucb, INC. | $484.62 | 2021-2025 | Rystiggo, Briviact, Fintepla |
| Lilly USA, LLC | $420.28 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Emd Serono, INC. | $395.25 | 2019-2024 | Mavenclad |
| Mdd US Operations, LLC | $383.80 | 2019-2025 | Qelbree, Gocovri |
| Celgene Corporation | $331.71 | 2024-2025 | Zeposia |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaveh Saremi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.